Literature DB >> 12065516

Glycoinositolphospholipids from Trypanosoma cruzi interfere with macrophages and dendritic cell responses.

Claudia Brodskyn1, Julie Patricio, Rubem Oliveira, Lucas Lobo, Andrea Arnholdt, Lucia Mendonça-Previato, Aldina Barral, Manoel Barral-Netto.   

Abstract

To investigate the possible effects of glycoinositolphospholipid (GIPL) from Trypanosoma cruzi on human antigen presenting cells, we tested their effects on lipopolysaccharide (LPS)-stimulated human macrophages and dendritic cells (DC). Human macrophages or DC were incubated with GIPL (50 microg/ml) and LPS (500 pg/ml) and tumor necrosis factor alpha (TNF-alpha), interleukin 8 (IL-8), IL-10, and IL-12p40 levels in supernatants were analyzed by enzyme-linked immunosorbent assay. TNF-alpha, IL-10, and IL-12 secretion were significantly decreased by GIPL both in macrophages and DC. In contrast, GIPL did not alter IL-8 production. We also analyzed the expression of CD80, CD86, HLA-DR, CD40, and CD57 on the macrophage surface after stimulation with LPS in the presence or absence of T. cruzi GIPL. GIPL led to a down-regulation in the expression of all tested molecules. We additionally examined the influence of T. cruzi GIPL on the response of human DC to LPS. LPS-induced HLA-DR, CD83, and CD86 up-regulation was significantly inhibited by GIPL. A slight down-regulation in CD80 and CD40 expression on DC surfaces in the presence of GIPL was also noticed. Similarly, GIPL led to down-modulation of CD83, CD80, CD86, and HLA-DR surface expression and TNF-alpha and IL-10 production when DC were stimulated by CD40L. The ceramide portion of GIPL was responsible for most of the activity exhibited by the whole molecule. Considering the important role of the immune response in determining the fate of the host-parasite relationship, the immunoregulatory activities of T. cruzi GIPL are potentially important for parasite evasion and then pathogenesis of infection with protozoan parasites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065516      PMCID: PMC128086          DOI: 10.1128/IAI.70.7.3736-3743.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Interleukin-12-mediated resistance to Trypanosoma cruzi is dependent on tumor necrosis factor alpha and gamma interferon.

Authors:  C A Hunter; T Slifer; F Araujo
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  Identification and characterization of protozoan products that trigger the synthesis of IL-12 by inflammatory macrophages.

Authors:  R T Gazzinelli; M M Camargo; I C Almeida; Y S Morita; M Giraldo; A Acosta-Serrano; S Hieny; P T Englund; M A Ferguson; L R Travassos; A Sher
Journal:  Chem Immunol       Date:  1997

3.  Proteophosphoglycan secreted by Leishmania mexicana amastigotes causes vacuole formation in macrophages.

Authors:  C Peters; Y D Stierhof; T Ilg
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

4.  Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway.

Authors:  V Verhasselt; C Buelens; F Willems; D De Groote; N Haeffner-Cavaillon; M Goldman
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

5.  Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes initiate the synthesis of proinflammatory cytokines by macrophages.

Authors:  M M Camargo; I C Almeida; M E Pereira; M A Ferguson; L R Travassos; R T Gazzinelli
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

6.  Structural variation in the glycoinositolphospholipids of different strains of Trypanosoma cruzi.

Authors:  J C Carreira; C Jones; R Wait; J O Previato; L Mendonça-Previato
Journal:  Glycoconj J       Date:  1996-12       Impact factor: 2.916

7.  Glycoinositolphospholipids purified from Trypanosoma cruzi stimulate Ig production in vitro.

Authors:  C A Bento; M B Melo; J O Previato; L Mendonça-Previato; L M Peçanha
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

8.  The lipid structure of the glycosylphosphatidylinositol-anchored mucin-like sialic acid acceptors of Trypanosoma cruzi changes during parasite differentiation from epimastigotes to infective metacyclic trypomastigote forms.

Authors:  A A Serrano; S Schenkman; N Yoshida; A Mehlert; J M Richardson; M A Ferguson
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

9.  Down-regulation of T lymphocyte activation in vitro and in vivo induced by glycoinositolphospholipids from Trypanosoma cruzi. Assignment of the T cell-suppressive determinant to the ceramide domain.

Authors:  N A Gomes; J O Previato; B Zingales; L Mendonça-Previato; G A DosReis
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

10.  Trypanosoma cruzi defined antigens in the serological evaluation of an outbreak of acute Chagas disease in Brazil (Catolé do Rocha, Paraíba).

Authors:  E S Umezawa; M A Shikanai-Yasuda; A Gruber; V L Pereira-Chioccola; B Zingales
Journal:  Mem Inst Oswaldo Cruz       Date:  1996 Jan-Feb       Impact factor: 2.743

View more
  26 in total

1.  Trypanosoma cruzi activates cord blood myeloid dendritic cells independently of cell infection.

Authors:  Patricia Rodriguez; Yves Carlier; Carine Truyens
Journal:  Med Microbiol Immunol       Date:  2012-02-12       Impact factor: 3.402

2.  Glycolipid sensing and innate immunity in paracoccidioidomycosis.

Authors:  Vanessa G Batista; Marcos S Toledo; Anita H Straus; Maria J S Mendes-Giannini; Alberto J S Duarte; Helio K Takahashi; Gil Benard
Journal:  Mycopathologia       Date:  2014-07-16       Impact factor: 2.574

Review 3.  Modulation of dendritic cell responses by parasites: a common strategy to survive.

Authors:  César A Terrazas; Luis I Terrazas; Lorena Gómez-García
Journal:  J Biomed Biotechnol       Date:  2010-02-24

4.  Activation of cord blood myeloid dendritic cells by Trypanosoma cruzi and parasite-specific antibodies, proliferation of CD8+ T cells, and production of IFN-γ.

Authors:  Patricia Rodriguez; Yves Carlier; Carine Truyens
Journal:  Med Microbiol Immunol       Date:  2011-10-29       Impact factor: 3.402

5.  Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection.

Authors:  Mustapha Chamekh; Vincent Vercruysse; Mohammed Habib; Maxime Lorent; Michel Goldman; Abdelmounaïm Allaoui; Bernard Vray
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation.

Authors:  Robert N Mahon; Obondo J Sande; Roxana E Rojas; Alan D Levine; Clifford V Harding; W Henry Boom
Journal:  Cell Immunol       Date:  2012-03-14       Impact factor: 4.868

7.  Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity.

Authors:  Paulo E A Souza; Manoel O C Rocha; Etel Rocha-Vieira; Cristiane A S Menezes; Andréa C L Chaves; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 8.  Activation and regulation of toll-like receptors (TLRs) by helminth parasites.

Authors:  Priyanka Goel Venugopal; Thomas B Nutman; Roshanak Tolouei Semnani
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

9.  Trypanosoma cruzi induces regulatory dendritic cells in vitro.

Authors:  Carolina Verónica Poncini; Catalina Dirney Alba Soto; Estela Batalla; Maria Elisa Solana; Stella Maris González Cappa
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

10.  Inhibition of HIV-1 replication in human monocyte-derived macrophages by parasite Trypanosoma cruzi.

Authors:  Guadalupe Andreani; Ana M Celentano; María E Solana; Silvia I Cazorla; Emilio L Malchiodi; Liliana A Martínez Peralta; Guillermina L Dolcini
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.